Elanco Animal Health Inc

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elanco Animal Health reports mixed 2022 results, eyes innovation growth

Elanco Animal Health's 2022 performance showed revenue decline but EPS growth, with a focus on innovation and portfolio strength for future growth.
The company aims to address challenges like competitive pressures and interest expenses while leveraging opportunities in product launches and margin improvement.
Financial projections include a net leverage ratio target for 2023, with plans for debt reduction and enhanced cash flow generation in the coming years.
Elanco's strategic focus on OTC parasiticides, innovation, and operational efficiency positions it well for sustained growth and market differentiation.

Elanco Animal Health reports Q1 growth and strategic outlook

Elanco Animal Health's Q1 2023 performance showcased revenue growth, strategic advancements, and improved cash flow generation, supported by successful ERP system integration benefits.
Despite challenges related to free cash flow, inventory discrepancies, and regulatory discussions, the company remains focused on optimizing working capital and enhancing financial metrics.
Opportunities lie in debt repayment, maintaining pricing benefits, upcoming product launches, and returning to growth in the second half of 2023, underpinned by global macro trends.
Elanco's strengths in market positioning, innovation progress, and strategic outlook for 2024 position the company for sustained growth and operational excellence in the animal health sector.

Elanco Animal Health surpasses Q2 targets, eyes global market growth

Elanco Animal Health exceeded Q2 targets, focusing on innovation and market expansion. While facing challenges in certain segments, the company is optimistic about future growth opportunities through differentiated products and global market strengths.

Elanco Animal Health excels in Q3, eyes sustained growth in 2024

Elanco Animal Health delivered a strong Q3 performance, emphasizing innovation and growth in international segments. While facing challenges in U.S. Pet Health and Farm Animal generics, the company is focused on driving sustainable growth through margin expansion and new product launches. Opportunities lie in upcoming blockbuster product launches and pricing strategies for 2024.

Elanco Animal Health reports growth in Q4 2023 earnings

Elanco Animal Health's Q4 2023 performance showed revenue growth driven by innovation and Farm Animal business strength.
Strategic restructuring aims to enhance efficiency and focus on pet health, while challenges include competitive pressures and margin headwinds.
Opportunities lie in continued growth, innovation, debt reduction, and commitment to new product sales targets.
Overall, Elanco remains confident in its position and ability to navigate market challenges.

Elanco Animal Health surpasses Q1 expectations, eyes revenue growth

Elanco Animal Health's Q1 2024 performance exceeded expectations, driven by strong Pet Health and Farm Animal segment growth, alongside improved cash flow and late-stage pipeline progress.
Despite challenges like product manufacturing issues and market queries, Elanco remains focused on innovation, market positioning, and executing its value agenda.
The company is poised for revenue growth, with positive outlooks for late-stage products and opportunities to capitalize on market demand and competitive strategies.
Elanco's strategic approach to product launches, market readiness, and portfolio expansion positions it well for future growth and market leadership.

Elanco Animal Health reports strong Q3 performance and growth outlook

Elanco Animal Health's Q3 performance reflects growth in key segments and products, with a focus on debt reduction and strategic investments.
The company faces challenges in competitive markets and supply chain transitions but is poised for growth through new product launches and market adoption.
Opportunities lie in expanding product reach, driving innovation sales, and navigating pricing trends to achieve mid-single-digit growth in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) (“Elanco”) today announced that as of 5:00 p.m., New York City time, on April 11, 2022 (the “Early Tender Time”), holders of approximately $406,391,000 aggregate principal amount, or approximately 54.19% of the outstanding principal amount, of its outstanding 4.272% Senior Notes due 2023 (the “Notes”) had tendered their Notes pursuant to Elanco's previously announced tender offer (the “Offer”). Elanco also announc

Elanco Animal Health Incorporated Announces Early Results of Tender Offer and Increase in Tender Cap for 2023 Notes

Ginkgo Bioworks Holdings

Elanco Animal Health Incorporated (NYSE: ELAN) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have launched BiomEdit, a microbiome innovation company. BiomEdit will discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines, and.

Elanco, Ginkgo Bioworks Launch BiomEdit, Microbiome-Focused Animal Health Firm

BiomEdit intends to discover and develop animal health products that leverage microbiome science to improve animal health, animal protein production, and livestock disease monitoring GREENFIELD, Ind. and BOSTON , April 11, 2022 /PRNewswire/ --  Elanco Animal Health Incorporated (NYSE: ELAN), a leading global animal health company, and  Ginkgo Bioworks , the leading horizontal platform for cell programming, today announced the launch of BiomEdit, a microbiome innovation company that is expected to discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health.

Elanco and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome Technology

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) (“Elanco”) today announced the commencement of a cash tender offer (the “Offer”) for up to $250 million aggregate principal amount of its 4.272% Senior Notes due 2023 (CUSIP No. 28414HAE3) (the “Notes”), upon the terms and conditions set forth in the Offer to Purchase dated March 29, 2022. The Offer is scheduled to expire at 12:00 midnight, New York City time, at the end of April 25, 2022 (unless extended) (the “E

Elanco Animal Health Incorporated Announces Tender Offer for 2023 Notes

Elanco's world-wide animal health business is growing and recession-resistant.

Elanco's Tangible Equity Units: Low Risk With A 6% Yield

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (ELAN: NYSE) today announces the expansion of its shared value footprint across Sub-Saharan Africa, delivering on its 2030 pledge to create sustainable development solutions for those who depend on livestock for their livelihoods. MAHABA (Managing Animal Health and Acaricides for a Better Africa) is Elanco's second shared value initiative and aims to support small-scale producers in Nigeria and Uganda by defining and implement

Elanco Expands Commitment to Creating Shared Value, Launches New Initiative Empowering Small-Scale Producers in Sub-Saharan Africa

Elanco Animal Health Incorporated (ELAN) CEO Jeff Simmons on Q4 2021 Results - Earnings Call Transcript

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 23.53% and 1.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Elanco Animal Health Incorporated (ELAN) Q4 Earnings and Revenues Beat Estimates

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2021, and provided initial guidance both for the first quarter and full year 2022. “2021 was a historic year for Elanco as we completed our independent company standup, continued our integration of Bayer Animal Health and recorded our highest revenue and adjusted EBITDA levels as a public company. We grew revenue 7 percent compared to our 20

Elanco Animal Health Reports Fourth Quarter and Full Year 2021 Results

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health (NYSE: ELAN) announced today the appointment of Rajeev (Bobby) Modi as the company's executive vice president U.S. Pet Health and Global Digital Transformation. He will join the company on March 14 and will serve on the company's executive committee. Modi most recently served as vice president and general manager of Enhancers and Components at Conagra Brands where he was responsible for the company's substantial Grocery business, positioni

Elanco Announces the Addition of Rajeev (Bobby) Modi to Lead U.S. Pet Health

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 2:50 p.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT ELANCO Elanco Animal Health (NYSE: ELAN) is a global leader i

Elanco to Participate in the Cowen 42nd Annual Health Care Conference

NORWALK, Conn., Feb. 8, 2022 /PRNewswire/ -- TriRx Pharmaceutical Services, LLC, a leading international CDMO, announced today that it has finalized and closed on its agreement with Elanco Animal Health Incorporated (NYSE:ELAN) to acquire the ownership and operations of its manufacturing site in Speke, United Kingdom.

TriRx Completes Acquisition of Elanco Manufacturing Facility in Speke, United Kingdom

GREENFIELD, Ind.--(BUSINESS WIRE)--As the urgent, time-sensitive issues of hunger and climate change lead headlines around the world, Elanco Animal Health (NYSE: ELAN) announces two new resources aimed at helping the cattle industry make a positive impact. According to the United Nations, the world only has until 2030 – just eight years – to curb emissions or see irreversible damage to the planet1. Meanwhile, the World Health Organization shows a full 60% of the world's population lacked proper

Elanco Adds New Tools to Advance U.S. Livestock Sustainability Efforts

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the BofA Securities 2022 Virtual Animal Health Summit on Thursday, February 24, 2022. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 1:35 p.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT ELANCO Elanco Animal Health (NYSE: ELAN) is a

Elanco to Participate in the BofA Securities 2022 Virtual Animal Health Summit

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will

Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2021 Financial Results Announcement

The FDA has approved Elanco Animal Health Inc (NYSE: ELAN) Zorbium (buprenorphine transdermal solution) to control postoperative pain associated with surgical procedures in cats. The approval expands Elanco's pain management offerings for veterinary practices.

Elanco's Long-Acting Transdermal Buprenorphine for Cats Gains FDA Approval

GREENFIELD, Ind.--(BUSINESS WIRE)--With the U.S. Food and Drug Administration (FDA) approval of Zorbium™ (buprenorphine transdermal solution), Elanco Animal Health (NYSE: ELAN) expands its pain management offerings while addressing an unmet need for veterinary practices. A new long-acting medication to control postoperative pain associated with surgical procedures in cats, ZORBIUM provides up to four days of pain control from a single transdermal dose. ZORBIUM is an innovative, transdermal form

Elanco's ZORBIUM™ (Buprenorphine Transdermal Solution) – the First Long-Acting Transdermal Buprenorphine for Cats - Gains U.S. Approval

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts. He is scheduled to present at 10:30 a.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT E

Elanco to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Elanco Animal Health Incorporated (NYSE: ELAN) will consolidate commercial operations for Elanco International and Elanco Europe into one organization under Ramiro Cabral, EVP & President Elanco International. The restructuring includes eliminating approximately 380 positions, including about 20% of Elanco's senior management.

Elanco To Lay Off 20% Senior Management In Organizational Restructure

Elanco Animal Health Inc. ELAN, -0.10% said Tuesday it will cut about 380 jobs globally as part of a restructuring aimed at simplifying the animal health company's organizational structure and to focus investments in priority areas. The job cuts, which represents about 3.7% of the workforce as of the end of 2020, will include reducing senior management by about 20%.

Elanco Animal Health to cut 380 jobs, reduce senior management by 20% as part of restructuring

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced proposed structural changes to simplify the organization as it best positions the company to create long-term value. The changes are intended to reduce organizational complexity, increase productivity, and enable investment in the highest growth and innovation opportunities, helping to offset previously disclosed higher cost pressures and maintaining the company's current path to 60% adjusted gross

Elanco Announces Changes to Simplify Organizational Structure, Drive Profitable Growth and Focus Investments on Growth and Innovation Opportunities

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 1:50 p.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 90 days. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELA

Elanco to Participate in the Evercore ISI 4th Annual HealthCONx Conference

GREENFIELD, Ind.--(BUSINESS WIRE)-- #AnimalsAreTheAnswer--Elanco Animal Health Incorporated (NYSE: ELAN) today announces its position as a founding member of the Greener Cattle Initiative, a research consortium that expects to award approximately $5 million over the next five years to support research into tangible, actionable solutions for potentially reducing enteric methane emissions from cattle, a key opportunity to help mitigate climate change. Led by the Foundation for Food & Agriculture Research (FFAR), ea

Elanco Joins Newly-Formed Consortium Advancing Climate-Neutral Cattle Innovation

Elanco Animal Health Incorporated's (ELAN) CEO Jeff Simmons on Q3 2021 Results - Earnings Call Transcript

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2021, provided guidance for the fourth quarter of 2021, and updated guidance for the full year 2021. The results reflect the inclusion of the Bayer Animal Health business Elanco acquired on August 1, 2020. "Our business continues to show good momentum and strong fundamentals since closing the Bayer Animal Health acquisition a year ago, now with our fourth c

News for Elanco Animal Health Inc Stock (ELAN)